OrganiGram Holdings Inc.
TSX:OGI.TO · Toronto Stock Exchange
-$0.02 today
Vol 0.07M · Avg 0.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-7.1%
avg -18.3%
ROIC
-13.0%
avg -16.5%
ROA
-4.4%
avg -15.1%
Analysis
ROA is currently the strongest return metric at -4.4% versus its period average of -15.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James H. Yamanaka | Chief Executive Officer & Director | $761,298.00 | — | 58 | — | — |
Timothy Emberg | President of Organigram Canada | $464,920.00 | — | — | — | — |
Greg Guyatt | Chief Financial Officer | $464,795.00 | — | — | — | — |
Helen Martin | Chief Legal Officer & Corporate Secretary | $462,703.00 | — | 48 | — | — |
Paolo De Luca | Chief Strategy Officer | $440,847.00 | — | 53 | — | — |
Peter L. Amirault | Executive Chairman | $95,000.00 | — | 65 | — | — |
Max Schwartz | Director of Investor Relations | — | — | — | — | — |
Nathalie Batten | Senior Vice President of Operations | — | — | — | — | — |
Megan Amber McCrae | Senior Vice President of Corporate Strategy & International Growth | — | — | — | — | — |
Valerie Rother | Chief People Officer | — | — | — | — | — |
Bradley Gunter | Senior Vice President of Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +8.7% (14yr)1 analysts |
| Revenue | N/A | N/A | N/A | +36.9% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | +26.6% (14yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +36.9% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
$408.80M
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
$360.97M
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
$323.08M
Medical Facilities Corporation
TSX:DR.TO
$315.73M
TerrAscend Corp.
TSX:TSND.TO
$284.80M
Aurora Cannabis Inc.
TSX:ACB.TO
$256.75M
Auxly Cannabis Group Inc.
TSX:XLY.TO
$250.54M
Canopy Growth Corporation
TSX:WEED.TO
$247.17M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Who manages OGI.TO?
OrganiGram Holdings Inc. (OGI.TO) lists 11 active executives. The top listed executive is James H. Yamanaka, Chief Executive Officer & Director.
Explore More
Continue the stock analysis
Jump to another research area for this company.